uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.137 | Q34 | What are the names of the genes that are targeted by the drug Neratinib Maleate in the treatment of breast cancer? | In the context of breast cancer, the drug Neratinib Maleate targets the gene epidermal growth factor receptor, erb-b2 receptor tyrosine kinase 2 and erb-b2 receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%neratinib maleate%" OR LOWER(tradeNames_list) LIKE "%neratinib maleate%" OR LOWER(syns_list) LIKE "%neratinib maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_209712', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209721', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209724', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209727', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209733', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209736', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209739', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209745', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209748', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209751', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209754', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209760', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209763', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209766', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209769', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209772', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209775', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209778', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209781', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209784', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209787', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209793', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209796', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209799', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209802', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209805', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209811', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209814', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209817', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209820', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209823', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209826', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209829', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209832', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209835', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209838', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209841', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209844', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209847', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209850', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209853', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209856', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209859', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209862', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209865', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209868', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209871', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209874', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209877', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209880', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209883', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209889', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209892', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209895', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209898', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209901', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209886', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209742', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209718', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209706', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209700', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209697', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209790', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209808', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209757', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209730', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209715', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209709', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209703', 'drugName': 'Neratinib Maleate', 'tradeNames_list': "['Nerlynx']", 'syns_list': "['Neratinib maleate', 'Neratinib maleate anhydrous']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.534 | Q34 | What are the names of the genes that are targeted by the drug Carbinoxamine Maleate in the treatment of vasomotor rhinitis? | In the context of vasomotor rhinitis, the drug Carbinoxamine Maleate targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%vasomotor rhinitis%" OR LOWER(efo_term) LIKE "%vasomotor rhinitis%") AND (LOWER(drugName) LIKE "%carbinoxamine maleate%" OR LOWER(tradeNames_list) LIKE "%carbinoxamine maleate%" OR LOWER(syns_list) LIKE "%carbinoxamine maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455852', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455858', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.397 | Q34 | What are the names of the genes that are targeted by the drug Fluocinolone Acetonide in the treatment of seborrheic dermatitis? | In the context of seborrheic dermatitis, the drug Fluocinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seborrheic dermatitis%" OR LOWER(efo_term) LIKE "%seborrheic dermatitis%") AND (LOWER(drugName) LIKE "%fluocinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%fluocinolone acetonide%" OR LOWER(syns_list) LIKE "%fluocinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242240', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242256', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.291 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of cancer? | In the context of cancer, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_228601', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228316', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232021', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231736', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226606', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230881', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226321', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228886', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227746', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229171', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229741', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230596', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227461', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232306', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229456', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227176', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230026', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226891', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230311', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228031', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231451', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231166', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226579', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231424', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229714', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226578', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229713', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231107', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231139', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231707', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226292', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231423', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230537', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227149', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227148', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231422', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231137', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227117', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228002', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230569', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227147', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231709', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229428', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228289', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229967', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230282', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230852', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230853', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231138', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229682', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231677', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229429', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226864', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226293', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227687', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226863', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226262', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229998', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231708', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228542', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228572', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229712', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227972', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230283', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229997', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230567', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230252', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228827', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229144', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227717', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227718', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227719', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228857', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229112', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226547', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228003', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229999', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228573', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227434', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227433', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229427', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229142', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230284', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227432', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229397', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228859', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228004', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228288', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227402', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228257', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230568', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228574', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228858', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226832', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229143', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226862', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230854', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230822', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226294', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231392', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.396 | Q34 | What are the names of the genes that are targeted by the drug Fluocinolone Acetonide in the treatment of hemorrhoid? | In the context of hemorrhoid, the drug Fluocinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhoid%" OR LOWER(efo_term) LIKE "%hemorrhoid%") AND (LOWER(drugName) LIKE "%fluocinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%fluocinolone acetonide%" OR LOWER(syns_list) LIKE "%fluocinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242239', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242255', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.249 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of epicondylitis? | In the context of epicondylitis, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epicondylitis%" OR LOWER(efo_term) LIKE "%epicondylitis%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222015', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222144', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222145', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222209', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222274', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222275', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222339', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222340', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222080', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221950', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221885', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221884', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222210', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222079', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222014', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221949', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1614 | Q34 | What are the names of the genes that are targeted by the drug Bivalirudin in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Bivalirudin targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%bivalirudin%" OR LOWER(tradeNames_list) LIKE "%bivalirudin%" OR LOWER(syns_list) LIKE "%bivalirudin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092328', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092311', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092362', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092345', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.111 | Q34 | What are the names of the genes that are targeted by the drug Duloxetine Hydrochloride in the treatment of unipolar depression? | In the context of unipolar depression, the drug Duloxetine Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%duloxetine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%duloxetine hydrochloride%" OR LOWER(syns_list) LIKE "%duloxetine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206076', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206124', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206140', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206156', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206188', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206204', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206220', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206252', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206268', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206284', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206300', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206332', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206348', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206364', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206380', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206396', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206412', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206428', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206444', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206460', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206476', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206492', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206236', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206108', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206044', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206012', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205996', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206316', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206172', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206092', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206060', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206028', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1769 | Q34 | What are the names of the genes that are targeted by the drug Ibandronate Sodium in the treatment of postmenopausal osteoporosis? | In the context of postmenopausal osteoporosis, the drug Ibandronate Sodium targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%postmenopausal osteoporosis%" OR LOWER(efo_term) LIKE "%postmenopausal osteoporosis%") AND (LOWER(drugName) LIKE "%ibandronate sodium%" OR LOWER(tradeNames_list) LIKE "%ibandronate sodium%" OR LOWER(syns_list) LIKE "%ibandronate sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099474', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099479', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099484', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1335 | Q34 | What are the names of the genes that are targeted by the drug Odevixibat in the treatment of Pruritus? | In the context of Pruritus, the drug Odevixibat targets the gene solute carrier family 10 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pruritus%" OR LOWER(efo_term) LIKE "%pruritus%") AND (LOWER(drugName) LIKE "%odevixibat%" OR LOWER(tradeNames_list) LIKE "%odevixibat%" OR LOWER(syns_list) LIKE "%odevixibat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_992746', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992767', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992774', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992781', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992795', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992802', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992809', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992823', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992830', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992837', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992844', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992858', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992865', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992872', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992879', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992886', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992893', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992900', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992907', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992914', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992921', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992935', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992942', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992949', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992956', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992963', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992977', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992984', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992991', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992998', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_993005', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_993012', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992928', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992816', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992760', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992732', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992718', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992711', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992970', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992851', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992788', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992753', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992739', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992725', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1480 | Q34 | What are the names of the genes that are targeted by the drug Lusutrombopag in the treatment of hemorrhage? | In the context of hemorrhage, the drug Lusutrombopag targets the gene MPL proto-oncogene, thrombopoietin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhage%" OR LOWER(efo_term) LIKE "%hemorrhage%") AND (LOWER(drugName) LIKE "%lusutrombopag%" OR LOWER(tradeNames_list) LIKE "%lusutrombopag%" OR LOWER(syns_list) LIKE "%lusutrombopag%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1056631', 'drugName': 'Lusutrombopag', 'tradeNames_list': "['Mulpleta', 'S-888711']", 'syns_list': "['Lusutrombopag', 'RSC888711', 'S-888711']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056628', 'drugName': 'Lusutrombopag', 'tradeNames_list': "['Mulpleta', 'S-888711']", 'syns_list': "['Lusutrombopag', 'RSC888711', 'S-888711']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056637', 'drugName': 'Lusutrombopag', 'tradeNames_list': "['Mulpleta', 'S-888711']", 'syns_list': "['Lusutrombopag', 'RSC888711', 'S-888711']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056634', 'drugName': 'Lusutrombopag', 'tradeNames_list': "['Mulpleta', 'S-888711']", 'syns_list': "['Lusutrombopag', 'RSC888711', 'S-888711']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.198 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of dermatitis herpetiformis? | In the context of dermatitis herpetiformis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dermatitis herpetiformis%" OR LOWER(efo_term) LIKE "%dermatitis herpetiformis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218704', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219328', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219536', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219744', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220160', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220368', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220576', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220784', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219120', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218288', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217872', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217664', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219952', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218912', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218496', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218080', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.548 | Q34 | What are the names of the genes that are targeted by the drug Levocetirizine Dihydrochloride in the treatment of Pruritus? | In the context of Pruritus, the drug Levocetirizine Dihydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pruritus%" OR LOWER(efo_term) LIKE "%pruritus%") AND (LOWER(drugName) LIKE "%levocetirizine dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%levocetirizine dihydrochloride%" OR LOWER(syns_list) LIKE "%levocetirizine dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455992', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_list': "['Levocetirizine dihydrochloride', 'Xusal', 'Xyzal', 'Xyzal allergy 24hrXyzall']", 'syns_list': "['Cetirizine (r)-form dihydrochloride', 'Cetirizine hydrochloride (r)-Levocetirizine dihydrochloride', 'Levocetirizine hydrochlorideLevocetirizine monohydrochloride', 'NSC-758898', 'UCB 28556', 'UCB-28556']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.299 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of ulcerative colitis? | In the context of ulcerative colitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ulcerative colitis%" OR LOWER(efo_term) LIKE "%ulcerative colitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227754', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228609', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228894', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229179', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229749', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230034', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230319', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230889', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231174', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231459', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231744', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232314', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230604', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228324', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227184', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226614', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226329', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232029', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229464', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228039', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227469', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226899', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.235 | Q34 | What are the names of the genes that are targeted by the drug Beclomethasone Dipropionate in the treatment of Rhinitis, Allergic, Perennial? | In the context of Rhinitis, Allergic, Perennial, the drug Beclomethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rhinitis, allergic, perennial%" OR LOWER(efo_term) LIKE "%rhinitis, allergic, perennial%") AND (LOWER(drugName) LIKE "%beclomethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%beclomethasone dipropionate%" OR LOWER(syns_list) LIKE "%beclomethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_221046', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221115', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221138', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221161', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221207', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221230', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221253', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221299', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221322', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221345', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221368', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221414', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221437', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221460', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221483', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221506', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221529', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221552', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221575', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221598', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221621', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221667', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221690', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221713', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221736', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221759', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221805', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221828', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221644', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221276', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221092', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221000', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220954', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220931', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221782', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221391', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221184', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221069', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221023', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220977', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.272 | Q34 | What are the names of the genes that are targeted by the drug Loteprednol Etabonate in the treatment of anterior uveitis? | In the context of anterior uveitis, the drug Loteprednol Etabonate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anterior uveitis%" OR LOWER(efo_term) LIKE "%anterior uveitis%") AND (LOWER(drugName) LIKE "%loteprednol etabonate%" OR LOWER(tradeNames_list) LIKE "%loteprednol etabonate%" OR LOWER(syns_list) LIKE "%loteprednol etabonate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225456', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225480', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225488', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225496', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225512', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225520', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225528', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225544', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225552', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225560', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225568', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225584', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225592', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225600', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225608', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225536', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225472', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225440', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225424', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225416', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225576', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225504', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225464', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225448', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225432', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Anterior', 'efo_term': 'anterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.656 | Q34 | What are the names of the genes that are targeted by the drug Desmopressin Acetate in the treatment of enuresis? | In the context of enuresis, the drug Desmopressin Acetate targets the gene arginine vasopressin receptor 2, arginine vasopressin receptor 1A and arginine vasopressin receptor 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%enuresis%" OR LOWER(efo_term) LIKE "%enuresis%") AND (LOWER(drugName) LIKE "%desmopressin acetate%" OR LOWER(tradeNames_list) LIKE "%desmopressin acetate%" OR LOWER(syns_list) LIKE "%desmopressin acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_694455', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694488', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694499', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694510', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694532', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694543', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694554', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694576', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694587', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694598', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694609', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694631', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694642', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694653', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694664', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694675', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694686', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694697', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694708', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694719', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694730', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694752', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694763', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694774', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694785', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694796', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694818', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694829', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694840', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694851', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694862', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694873', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694884', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694895', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694906', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694917', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694928', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694939', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694950', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694961', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694972', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694983', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694994', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695005', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695016', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695027', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695038', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695049', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695060', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695071', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695082', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694741', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694565', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694477', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694433', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694411', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694400', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694807', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694620', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694521', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694466', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694444', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694422', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nocturnal Enuresis', 'efo_term': 'enuresis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1743 | Q34 | What are the names of the genes that are targeted by the drug Esomeprazole Magnesium in the treatment of Esophagitis? | In the context of Esophagitis, the drug Esomeprazole Magnesium targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%esophagitis%" OR LOWER(efo_term) LIKE "%esophagitis%") AND (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_list) LIKE "%esomeprazole magnesium%" OR LOWER(syns_list) LIKE "%esomeprazole magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097870', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097858', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097894', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097882', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.499 | Q34 | What are the names of the genes that are targeted by the drug Methylphenidate Hydrochloride in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Methylphenidate Hydrochloride targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%methylphenidate hydrochloride%" OR LOWER(tradeNames_list) LIKE "%methylphenidate hydrochloride%" OR LOWER(syns_list) LIKE "%methylphenidate hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_435220', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435253', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435264', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435275', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435297', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435308', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435319', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435341', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435352', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435363', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435374', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435396', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435407', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435418', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435429', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435440', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435451', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435462', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435473', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435484', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435495', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435517', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435528', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435539', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435550', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435561', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435583', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435594', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435605', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435616', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435627', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435638', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435649', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435660', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435671', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435682', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435693', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435704', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435715', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435726', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435737', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435748', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435759', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435770', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435781', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435792', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435803', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435814', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435825', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435836', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435847', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435869', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435880', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435891', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435902', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435913', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435924', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435946', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435957', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435968', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435979', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435990', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436001', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436012', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436023', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436034', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436045', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436056', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436067', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436078', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436089', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436100', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436111', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436122', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436133', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436144', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436155', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436166', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436177', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436188', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436199', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436210', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436221', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436232', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436243', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436254', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435858', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435506', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435330', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435242', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435198', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435176', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435165', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435935', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435572', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435385', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435286', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435231', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435209', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435187', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1425 | Q34 | What are the names of the genes that are targeted by the drug Lomitapide Mesylate in the treatment of familial hypercholesterolemia? | In the context of familial hypercholesterolemia, the drug Lomitapide Mesylate targets the gene microsomal triglyceride transfer protein and prolyl 4-hydroxylase subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial hypercholesterolemia%" OR LOWER(efo_term) LIKE "%familial hypercholesterolemia%") AND (LOWER(drugName) LIKE "%lomitapide mesylate%" OR LOWER(tradeNames_list) LIKE "%lomitapide mesylate%" OR LOWER(syns_list) LIKE "%lomitapide mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1042956', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042963', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042964', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042967', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042971', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042972', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042975', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042979', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042980', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042983', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042984', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042988', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042991', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042992', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042995', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042996', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042999', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043000', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043003', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043004', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043007', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043011', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043012', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043015', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043016', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043019', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043023', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043024', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043027', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043028', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043031', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043032', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043035', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043036', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043039', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043040', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043043', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043044', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043047', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043048', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043051', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043052', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043055', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043056', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043059', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043060', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043063', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043064', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043067', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043068', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043071', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043075', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043076', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043079', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043080', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043083', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043084', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043088', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043091', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043092', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043095', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043096', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043099', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043100', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043103', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043104', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043107', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043108', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043111', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043112', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043115', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043116', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043119', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043120', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043123', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043124', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043127', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043128', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043131', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043132', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043135', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043136', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043139', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1043140', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1043143', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1043144', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'P4HB', 'approvedName': 'prolyl 4-hydroxylase subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1043072', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043008', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042976', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042960', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042952', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042948', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042947', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043087', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1043020', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042987', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042968', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042959', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042955', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}, {'UUID': 'DrugTargetsIndication121923_text_1042951', 'drugName': 'Lomitapide Mesylate', 'tradeNames_list': "['Juxtapid']", 'syns_list': "['AEGR-733', 'AEGR-733 MESYLATE', 'Aegr-733 mesilate', 'BMS-201038BMS-201038-04', 'Lomitapide mesilate', 'Lomitapide mesylate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'MTTP', 'approvedName': 'microsomal triglyceride transfer protein'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1551 | Q34 | What are the names of the genes that are targeted by the drug Suvorexant in the treatment of insomnia? | In the context of insomnia, the drug Suvorexant targets the gene hypocretin receptor 2 and hypocretin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%insomnia%" OR LOWER(efo_term) LIKE "%insomnia%") AND (LOWER(drugName) LIKE "%suvorexant%" OR LOWER(tradeNames_list) LIKE "%suvorexant%" OR LOWER(syns_list) LIKE "%suvorexant%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1076513', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076543', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076553', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076563', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076583', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076593', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076603', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076613', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076533', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076493', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076473', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076463', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076573', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076523', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076503', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076483', 'drugName': 'Suvorexant', 'tradeNames_list': "['Belsomra']", 'syns_list': "['MK-4305', 'MK4305', 'Suvorexant']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.253 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of dermatitis? | In the context of dermatitis, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dermatitis%" OR LOWER(efo_term) LIKE "%dermatitis%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222018', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221953', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222343', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222213', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221888', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222278', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222083', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222148', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis', 'efo_term': 'dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222096', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222161', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222291', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221966', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221901', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221836', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222226', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222031', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.824 | Q34 | What are the names of the genes that are targeted by the drug Nepafenac in the treatment of cataract? | In the context of cataract, the drug Nepafenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cataract%" OR LOWER(efo_term) LIKE "%cataract%") AND (LOWER(drugName) LIKE "%nepafenac%" OR LOWER(tradeNames_list) LIKE "%nepafenac%" OR LOWER(syns_list) LIKE "%nepafenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828612', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828627', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828632', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828637', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828622', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828602', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828592', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828587', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828642', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828617', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828607', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828597', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1850 | Q34 | What are the names of the genes that are targeted by the drug Simvastatin in the treatment of acute myocardial infarction? | In the context of acute myocardial infarction, the drug Simvastatin targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute myocardial infarction%" OR LOWER(efo_term) LIKE "%acute myocardial infarction%") AND (LOWER(drugName) LIKE "%simvastatin%" OR LOWER(tradeNames_list) LIKE "%simvastatin%" OR LOWER(syns_list) LIKE "%simvastatin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103902', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103798', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104110', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104006', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1294 | Q34 | What are the names of the genes that are targeted by the drug Glucagon in the treatment of Hypoglycemia? | In the context of Hypoglycemia, the drug Glucagon targets the gene glucagon receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypoglycemia%" OR LOWER(efo_term) LIKE "%hypoglycemia%") AND (LOWER(drugName) LIKE "%glucagon%" OR LOWER(tradeNames_list) LIKE "%glucagon%" OR LOWER(syns_list) LIKE "%glucagon%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_968350', 'drugName': 'Dasiglucagon Hydrochloride', 'tradeNames_list': "['Zegalogue', 'Zegalogue (autoinjector)']", 'syns_list': "['Dasiglucagon hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968324', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968292', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968340', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968348', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968316', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968300', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968308', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968352', 'drugName': 'Dasiglucagon Hydrochloride', 'tradeNames_list': "['Zegalogue', 'Zegalogue (autoinjector)']", 'syns_list': "['Dasiglucagon hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968332', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968297', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nesidioblastosis', 'efo_term': 'hyperinsulinemic hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968329', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nesidioblastosis', 'efo_term': 'hyperinsulinemic hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968337', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nesidioblastosis', 'efo_term': 'hyperinsulinemic hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968345', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nesidioblastosis', 'efo_term': 'hyperinsulinemic hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968289', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nesidioblastosis', 'efo_term': 'hyperinsulinemic hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968305', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nesidioblastosis', 'efo_term': 'hyperinsulinemic hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968321', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nesidioblastosis', 'efo_term': 'hyperinsulinemic hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968313', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nesidioblastosis', 'efo_term': 'hyperinsulinemic hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1229 | Q34 | What are the names of the genes that are targeted by the drug Ribavirin in the treatment of chronic hepatitis C virus infection? | In the context of chronic hepatitis C virus infection, the drug Ribavirin targets the gene inosine monophosphate dehydrogenase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic hepatitis c virus infection%" OR LOWER(efo_term) LIKE "%chronic hepatitis c virus infection%") AND (LOWER(drugName) LIKE "%ribavirin%" OR LOWER(tradeNames_list) LIKE "%ribavirin%" OR LOWER(syns_list) LIKE "%ribavirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937566', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}, {'UUID': 'DrugTargetsIndication121923_text_937591', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.277 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Furoate in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Fluticasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%fluticasone furoate%" OR LOWER(tradeNames_list) LIKE "%fluticasone furoate%" OR LOWER(syns_list) LIKE "%fluticasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225660', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225687', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225696', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225705', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225723', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225732', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225741', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225759', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225768', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225777', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225786', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225804', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225813', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225822', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225831', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225840', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225849', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225858', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225867', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225876', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225885', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225903', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225912', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225921', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225930', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225939', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225957', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225966', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225975', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225984', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225993', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226002', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226011', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226020', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226029', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226038', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226047', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226056', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226065', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226074', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226083', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226092', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226101', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225894', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225750', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225678', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225642', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225624', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225615', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225948', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225795', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225714', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225669', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225651', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225633', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.386 | Q34 | What are the names of the genes that are targeted by the drug Mometasone Furoate in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Mometasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%mometasone furoate%" OR LOWER(tradeNames_list) LIKE "%mometasone furoate%" OR LOWER(syns_list) LIKE "%mometasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242040', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242118', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242144', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242170', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242222', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242092', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241988', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241936', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241910', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242196', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242066', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242014', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241962', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.956 | Q34 | What are the names of the genes that are targeted by the drug Bromfenac Sodium in the treatment of inflammation? | In the context of inflammation, the drug Bromfenac Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%inflammation%" OR LOWER(efo_term) LIKE "%inflammation%") AND (LOWER(drugName) LIKE "%bromfenac sodium%" OR LOWER(tradeNames_list) LIKE "%bromfenac sodium%" OR LOWER(syns_list) LIKE "%bromfenac sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842558', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842567', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842570', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842573', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842579', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842582', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842585', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842591', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842594', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842597', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842600', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842606', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842609', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842612', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842588', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842564', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842552', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842546', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842543', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842603', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842576', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842561', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842555', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842549', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1973 | Q34 | What are the names of the genes that are targeted by the drug Topotecan Hydrochloride in the treatment of small cell carcinoma? | In the context of small cell carcinoma, the drug Topotecan Hydrochloride targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%small cell carcinoma%" OR LOWER(efo_term) LIKE "%small cell carcinoma%") AND (LOWER(drugName) LIKE "%topotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%topotecan hydrochloride%" OR LOWER(syns_list) LIKE "%topotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193576', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Small Cell', 'efo_term': 'small cell carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193648', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Small Cell', 'efo_term': 'small cell carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1012 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857478', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.819 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of rheumatic disease? | In the context of rheumatic disease, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatic disease%" OR LOWER(efo_term) LIKE "%rheumatic disease%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828376', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828478', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828512', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828546', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828444', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828308', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828240', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828206', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828580', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828410', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828342', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828274', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1870 | Q34 | What are the names of the genes that are targeted by the drug Lenalidomide in the treatment of multiple myeloma? | In the context of multiple myeloma, the drug Lenalidomide targets the gene cereblon, damage specific DNA binding protein 1, cullin 4A and ring-box 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple myeloma%" OR LOWER(efo_term) LIKE "%multiple myeloma%") AND (LOWER(drugName) LIKE "%lenalidomide%" OR LOWER(tradeNames_list) LIKE "%lenalidomide%" OR LOWER(syns_list) LIKE "%lenalidomide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1112696', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108781', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111304', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109477', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107911', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113479', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108259', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108607', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110608', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108955', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111478', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111913', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109651', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113044', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107824', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113131', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107998', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113653', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108172', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113740', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108346', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108520', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110260', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108694', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110782', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108868', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109042', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111826', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109216', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111565', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109390', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112087', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109564', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112174', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109738', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113392', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109912', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112957', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106171', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113305', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106780', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113218', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105910', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114088', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106867', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113566', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106258', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114001', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106954', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113914', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113827', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107041', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110086', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106345', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110434', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107128', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110347', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111130', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107215', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110695', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106432', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111043', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107302', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110956', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105823', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112522', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107389', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111391', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106519', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111739', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107476', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111652', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106084', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112435', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107563', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112000', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106606', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112348', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107650', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112261', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105736', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114175', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107737', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112783', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106693', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114349', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114262', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112609', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111217', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110521', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110173', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109999', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108433', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105997', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110869', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109303', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112870', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108085', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109129', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109825', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.190 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of optic neuritis? | In the context of optic neuritis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%optic neuritis%" OR LOWER(efo_term) LIKE "%optic neuritis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218696', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219320', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219528', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219736', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220152', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220360', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220568', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220776', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219112', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218280', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217864', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217656', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219944', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218904', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218488', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218072', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1279 | Q34 | What are the names of the genes that are targeted by the drug Entrectinib in the treatment of neoplasm? | In the context of neoplasm, the drug Entrectinib targets the gene neurotrophic receptor tyrosine kinase 1, ALK receptor tyrosine kinase, neurotrophic receptor tyrosine kinase 2, neurotrophic receptor tyrosine kinase 3 and ROS proto-oncogene 1, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%entrectinib%" OR LOWER(tradeNames_list) LIKE "%entrectinib%" OR LOWER(syns_list) LIKE "%entrectinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_942980', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942993', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942994', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943000', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943007', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943008', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943014', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943021', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943022', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943028', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943029', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943036', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943042', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943043', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943049', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943050', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943056', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943057', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943063', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943064', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943070', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943077', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943078', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943084', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943085', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943091', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943098', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943099', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943105', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943106', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943112', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943113', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943119', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943120', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943126', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943127', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943133', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943134', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943140', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943141', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943147', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943148', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943154', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943155', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943161', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943162', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943168', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943169', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943175', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943176', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943182', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943189', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943190', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943196', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943197', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943203', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943204', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943211', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943217', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943218', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943224', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943225', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943231', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943232', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943238', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943239', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943245', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943246', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943252', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943253', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943259', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943260', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943266', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943267', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943273', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943274', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943280', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943281', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943287', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943288', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943294', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943295', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943301', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943302', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943308', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943309', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943183', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943071', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943015', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942987', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942973', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942966', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942965', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943210', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943092', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943035', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943001', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942986', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942979', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942972', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1640 | Q34 | What are the names of the genes that are targeted by the drug Avanafil in the treatment of erectile dysfunction? | In the context of erectile dysfunction, the drug Avanafil targets the gene phosphodiesterase 5A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%erectile dysfunction%" OR LOWER(efo_term) LIKE "%erectile dysfunction%") AND (LOWER(drugName) LIKE "%avanafil%" OR LOWER(tradeNames_list) LIKE "%avanafil%" OR LOWER(syns_list) LIKE "%avanafil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094069', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'syns_list': "['Avanafil', 'TA-1790']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094061', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'syns_list': "['Avanafil', 'TA-1790']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094059', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'syns_list': "['Avanafil', 'TA-1790']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094065', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'syns_list': "['Avanafil', 'TA-1790']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094067', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'syns_list': "['Avanafil', 'TA-1790']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094063', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'syns_list': "['Avanafil', 'TA-1790']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1595 | Q34 | What are the names of the genes that are targeted by the drug Safinamide Mesylate in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Safinamide Mesylate targets the gene monoamine oxidase B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%safinamide mesylate%" OR LOWER(tradeNames_list) LIKE "%safinamide mesylate%" OR LOWER(syns_list) LIKE "%safinamide mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091647', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091643', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091642', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091645', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091646', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091644', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1781 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of osteoporosis? | In the context of osteoporosis, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoporosis%" OR LOWER(efo_term) LIKE "%osteoporosis%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099713', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099822', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099823', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099877', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099932', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099933', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099987', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100042', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100043', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100097', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100098', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100153', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100207', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100208', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099988', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099768', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099658', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099603', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099602', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100152', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099878', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099767', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099712', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099657', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.762 | Q34 | What are the names of the genes that are targeted by the drug Naltrexone in the treatment of alcohol dependence? | In the context of alcohol dependence, the drug Naltrexone targets the gene opioid receptor mu 1, opioid receptor kappa 1 and opioid receptor delta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%alcohol dependence%" OR LOWER(efo_term) LIKE "%alcohol dependence%") AND (LOWER(drugName) LIKE "%naltrexone%" OR LOWER(tradeNames_list) LIKE "%naltrexone%" OR LOWER(syns_list) LIKE "%naltrexone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_785290', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1'}, {'UUID': 'DrugTargetsIndication121923_text_785110', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785065', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785200', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_785245', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1'}, {'UUID': 'DrugTargetsIndication121923_text_785155', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1097 | Q34 | What are the names of the genes that are targeted by the drug Testosterone in the treatment of Hypogonadotropic hypogonadism? | In the context of Hypogonadotropic hypogonadism, the drug Testosterone targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypogonadotropic hypogonadism%" OR LOWER(efo_term) LIKE "%hypogonadotropic hypogonadism%") AND (LOWER(drugName) LIKE "%testosterone%" OR LOWER(tradeNames_list) LIKE "%testosterone%" OR LOWER(syns_list) LIKE "%testosterone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921410', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921437', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921446', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921455', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921473', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921482', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921491', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921509', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921518', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921527', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921536', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921554', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921563', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921572', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921581', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921590', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921599', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921608', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921617', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921626', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921635', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921653', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921662', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921671', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921680', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921689', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921707', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921716', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921725', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921734', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921743', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921752', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921761', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921770', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921779', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921788', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921797', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921806', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921815', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921824', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921833', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921842', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921976', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921989', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922002', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922015', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922028', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922041', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922054', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922067', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922080', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922106', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922119', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922132', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922145', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922158', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922171', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922197', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922210', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922223', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922236', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922249', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922262', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922275', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922288', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922301', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922314', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922327', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922340', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922353', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922366', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922379', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922392', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922405', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922418', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922431', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922444', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922457', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922470', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922483', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922496', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922524', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922528', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922560', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922564', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922596', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922093', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921644', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921500', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921428', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921392', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921374', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921365', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922184', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921698', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921545', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921464', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921419', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921401', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921383', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.256 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_221891', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222216', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222086', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222281', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222151', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222021', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221956', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222346', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221928', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221853', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222048', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222058', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222243', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221918', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222178', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221983', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221993', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221863', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222188', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222318', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222308', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222253', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222113', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222123', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1333 | Q34 | What are the names of the genes that are targeted by the drug Maralixibat Chloride in the treatment of Pruritus? | In the context of Pruritus, the drug Maralixibat Chloride targets the gene solute carrier family 10 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pruritus%" OR LOWER(efo_term) LIKE "%pruritus%") AND (LOWER(drugName) LIKE "%maralixibat chloride%" OR LOWER(tradeNames_list) LIKE "%maralixibat chloride%" OR LOWER(syns_list) LIKE "%maralixibat chloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_992696', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'syns_list': "['LUM-001', 'LUM001', 'Lopixibat chloride', 'Maralixibat chloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992700', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'syns_list': "['LUM-001', 'LUM001', 'Lopixibat chloride', 'Maralixibat chloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992704', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'syns_list': "['LUM-001', 'LUM001', 'Lopixibat chloride', 'Maralixibat chloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1244 | Q34 | What are the names of the genes that are targeted by the drug Maraviroc in the treatment of HIV infection? | In the context of HIV infection, the drug Maraviroc targets the gene C-C motif chemokine receptor 5. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hiv infection%" OR LOWER(efo_term) LIKE "%hiv infection%") AND (LOWER(drugName) LIKE "%maraviroc%" OR LOWER(tradeNames_list) LIKE "%maraviroc%" OR LOWER(syns_list) LIKE "%maraviroc%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938328', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938368', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938370', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938389', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938410', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938412', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938431', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938452', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938454', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938473', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938475', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938496', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938515', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938517', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938536', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938538', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938557', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938559', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938578', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938580', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938433', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938349', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938307', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938286', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938284', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938494', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938391', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938347', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938326', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938305', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1470 | Q34 | What are the names of the genes that are targeted by the drug Monomethyl Fumarate in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Monomethyl Fumarate targets the gene kelch like ECH associated protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%monomethyl fumarate%" OR LOWER(tradeNames_list) LIKE "%monomethyl fumarate%" OR LOWER(syns_list) LIKE "%monomethyl fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055635', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055649', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055663', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055645', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055661', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055659', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055631', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055637', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055647', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055643', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055653', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055665', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055639', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055655', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055651', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055633', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055667', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055657', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055641', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055640', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055650', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055652', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055660', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055632', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055642', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055654', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055666', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055656', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055636', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055630', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055634', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055638', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055646', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055662', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055664', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055648', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055658', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055644', 'drugName': 'Monomethyl Fumarate', 'tradeNames_list': "['Bafiertam']", 'syns_list': "['Fumaric acid monomethyl ester', 'Methyl Fumarate', 'Monomethyl fumarateNSC-523835']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.423 | Q34 | What are the names of the genes that are targeted by the drug Fenofibrate in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Fenofibrate targets the gene peroxisome proliferator activated receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%fenofibrate%" OR LOWER(tradeNames_list) LIKE "%fenofibrate%" OR LOWER(syns_list) LIKE "%fenofibrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243843', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243861', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243867', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243873', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243885', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243891', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243897', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243942', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243971', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244000', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244029', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244087', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244116', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244145', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244174', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244203', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244232', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244261', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244290', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244319', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244348', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244406', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244435', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244377', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243903', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243855', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243819', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243813', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243831', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244058', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243879', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243849', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243837', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243825', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.717 | Q34 | What are the names of the genes that are targeted by the drug Vemurafenib in the treatment of cutaneous melanoma? | In the context of cutaneous melanoma, the drug Vemurafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cutaneous melanoma%" OR LOWER(efo_term) LIKE "%cutaneous melanoma%") AND (LOWER(drugName) LIKE "%vemurafenib%" OR LOWER(tradeNames_list) LIKE "%vemurafenib%" OR LOWER(syns_list) LIKE "%vemurafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752200', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752158', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752116', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752095', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752221', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752179', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752137', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.258 | Q34 | What are the names of the genes that are targeted by the drug Budesonide in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Budesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%budesonide%" OR LOWER(tradeNames_list) LIKE "%budesonide%" OR LOWER(syns_list) LIKE "%budesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222609', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222744', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222789', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222834', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222924', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222969', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223014', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223104', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223149', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223194', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223239', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223329', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223374', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223419', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223464', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223509', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223554', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223599', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223644', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223689', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223734', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223824', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223869', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223914', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223959', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224004', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224094', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224139', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224184', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224229', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224274', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224319', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224364', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224409', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224454', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224499', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224544', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224589', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224634', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224679', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224724', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224769', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224814', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224859', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224904', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224949', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224994', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225039', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225084', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225129', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225174', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225264', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225309', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225354', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225399', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225219', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223779', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222699', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222519', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222429', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222384', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223059', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224049', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223284', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222879', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222654', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222564', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222474', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.24 | Q34 | What are the names of the genes that are targeted by the drug Brexpiprazole in the treatment of unipolar depression? | In the context of unipolar depression, the drug Brexpiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%brexpiprazole%" OR LOWER(tradeNames_list) LIKE "%brexpiprazole%" OR LOWER(syns_list) LIKE "%brexpiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155831', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155873', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155887', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155901', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155929', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155943', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155957', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155985', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155999', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156013', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156027', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156055', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156069', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156083', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156097', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156111', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156125', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156139', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156153', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156167', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156181', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156209', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156223', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156237', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156251', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156265', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156293', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156307', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156321', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156335', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156349', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156363', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156377', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156391', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156405', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156419', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156433', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156447', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156461', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156475', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156489', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156503', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156517', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156531', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156545', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156559', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156573', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156587', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156601', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156615', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156629', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156657', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156671', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156685', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156699', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156713', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156727', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156755', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156769', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156783', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156797', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156811', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156825', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156839', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156853', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156867', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156881', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156895', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156909', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156923', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156937', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156951', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156965', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156979', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156993', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157007', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157021', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157035', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157049', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157063', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157077', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157091', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157105', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157119', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157133', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157147', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156643', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156195', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155971', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155859', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155803', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155775', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155761', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156741', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156279', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156041', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155915', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155845', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155817', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155789', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1400 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline Hyclate in the treatment of acne? | In the context of acne, the drug Doxycycline Hyclate targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acne%" OR LOWER(efo_term) LIKE "%acne%") AND (LOWER(drugName) LIKE "%doxycycline hyclate%" OR LOWER(tradeNames_list) LIKE "%doxycycline hyclate%" OR LOWER(syns_list) LIKE "%doxycycline hyclate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1036879', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036912', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036923', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036934', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036956', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036967', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036978', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037000', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037011', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037022', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037033', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037055', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037066', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037077', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037088', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037099', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037110', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037121', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037132', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037143', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037154', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037176', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037187', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037198', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037209', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037220', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037242', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037253', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037264', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037275', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037286', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037297', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037308', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037319', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037330', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037341', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037352', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037363', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037374', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037385', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037396', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037407', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037418', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037429', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037440', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037451', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037462', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037473', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037484', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037495', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037506', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037528', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037539', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037550', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037561', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037572', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037583', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037605', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037616', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037627', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037638', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037649', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037660', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037671', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037682', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037693', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037704', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037715', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037726', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037737', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037748', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037759', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037770', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037781', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037517', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037165', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036989', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036901', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036857', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036835', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036824', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037594', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037231', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037044', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036945', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036890', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036868', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036846', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.64 | Q34 | What are the names of the genes that are targeted by the drug Metoclopramide Hydrochloride in the treatment of cancer? | In the context of cancer, the drug Metoclopramide Hydrochloride targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 3A and 5-hydroxytryptamine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%metoclopramide hydrochloride%" OR LOWER(tradeNames_list) LIKE "%metoclopramide hydrochloride%" OR LOWER(syns_list) LIKE "%metoclopramide hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199702', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199670', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199662', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199686', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199694', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199678', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.957 | Q34 | What are the names of the genes that are targeted by the drug Bromfenac Sodium in the treatment of cataract? | In the context of cataract, the drug Bromfenac Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cataract%" OR LOWER(efo_term) LIKE "%cataract%") AND (LOWER(drugName) LIKE "%bromfenac sodium%" OR LOWER(tradeNames_list) LIKE "%bromfenac sodium%" OR LOWER(syns_list) LIKE "%bromfenac sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842559', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842568', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842571', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842574', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842580', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842583', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842586', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842592', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842595', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842598', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842601', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842607', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842610', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842613', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842589', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842565', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842553', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842547', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842544', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842604', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842577', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842562', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842556', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842550', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1225 | Q34 | What are the names of the genes that are targeted by the drug Sumatriptan Succinate in the treatment of migraine disorder? | In the context of migraine disorder, the drug Sumatriptan Succinate targets the gene 5-hydroxytryptamine receptor 1B and 5-hydroxytryptamine receptor 1D. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%sumatriptan succinate%" OR LOWER(tradeNames_list) LIKE "%sumatriptan succinate%" OR LOWER(syns_list) LIKE "%sumatriptan succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937284', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937293', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937296', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937299', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937305', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937308', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937311', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937317', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937320', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937323', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937326', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937332', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937335', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937338', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937341', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937344', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937347', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937350', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937353', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937356', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937359', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937365', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937368', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937371', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937374', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937377', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937383', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937386', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937389', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937392', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937395', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937398', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937401', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937404', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937407', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937410', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937413', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937416', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937419', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937422', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937425', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937428', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937431', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937434', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937437', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937440', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937443', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937446', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937449', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937452', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937455', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937461', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937464', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937467', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937470', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937473', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937476', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937482', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937485', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937488', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937491', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937494', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937497', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937500', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937503', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937506', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937509', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937512', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937515', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937518', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937521', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937524', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937527', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937530', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937533', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937536', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937458', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937362', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937314', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937290', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937278', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937272', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937269', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937479', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937380', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937329', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937302', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937287', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937281', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_937275', 'drugName': 'Sumatriptan Succinate', 'tradeNames_list': "['Alsuma', 'Imigran', 'Imigran 50', 'Imigran radis', 'Imigran recoveryImigran subject', 'Imitrex', 'Imitrex statdose', 'MigraitanMigraleve ultra', 'Onzetra xsail', 'Sumatriptan succinateSumavel dosepro', 'Zecuity', 'Zembrace symtouch']", 'syns_list': "['GR 43175C', 'GR-43175C', 'NSC-760362', 'Sumatriptan (as succinate)Sumatriptan galpharm', 'Sumatriptan succinate', 'Treximet']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1B', 'approvedName': '5-hydroxytryptamine receptor 1B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.308 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of eye disease? | In the context of eye disease, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye disease%" OR LOWER(efo_term) LIKE "%eye disease%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226915', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227478', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227485', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227763', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228048', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228055', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228333', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228618', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228625', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228903', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228910', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229195', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229473', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229480', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229758', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229765', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230043', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230050', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230328', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230335', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230613', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230898', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230905', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231183', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231190', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231468', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231753', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231760', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232038', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232045', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232323', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232330', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230620', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228340', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227200', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226630', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226345', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226338', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231475', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229188', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227770', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227193', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226908', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226623', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1125 | Q34 | What are the names of the genes that are targeted by the drug Binimetinib in the treatment of melanoma? | In the context of melanoma, the drug Binimetinib targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%melanoma%" OR LOWER(efo_term) LIKE "%melanoma%") AND (LOWER(drugName) LIKE "%binimetinib%" OR LOWER(tradeNames_list) LIKE "%binimetinib%" OR LOWER(syns_list) LIKE "%binimetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_926681', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926707', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926730', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926732', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926756', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926758', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926759', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926784', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926785', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926808', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926810', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926834', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926836', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926837', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926860', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926862', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926863', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926886', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926888', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926889', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926912', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926915', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926938', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926940', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926941', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926964', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926967', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926990', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926992', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926993', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927016', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927018', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927019', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927042', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927044', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927045', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927068', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927070', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927071', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927094', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927096', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927097', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927120', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927122', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927123', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927146', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927148', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927149', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926914', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926782', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926706', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926678', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926654', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926652', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926966', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926811', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926733', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926704', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926680', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926655', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.738 | Q34 | What are the names of the genes that are targeted by the drug Naldemedine Tosylate in the treatment of constipation disorder? | In the context of constipation disorder, the drug Naldemedine Tosylate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%constipation disorder%" OR LOWER(efo_term) LIKE "%constipation disorder%") AND (LOWER(drugName) LIKE "%naldemedine tosylate%" OR LOWER(tradeNames_list) LIKE "%naldemedine tosylate%" OR LOWER(syns_list) LIKE "%naldemedine tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763379', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763376', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763385', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763382', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.565 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of Ventricular arrhythmia? | In the context of Ventricular arrhythmia, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ventricular arrhythmia%" OR LOWER(efo_term) LIKE "%ventricular arrhythmia%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638354', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638699', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638814', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638929', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639159', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639274', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639389', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639619', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639734', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639849', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639964', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640194', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640309', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640424', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640539', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640654', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640769', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640884', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640999', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641114', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641229', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641459', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641574', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641689', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641804', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641919', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642149', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642264', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642379', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642494', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642609', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642724', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642839', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642954', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643069', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643184', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643299', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643414', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643529', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643644', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643759', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643874', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643989', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644104', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644219', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644334', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644449', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644564', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641344', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639504', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638584', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638124', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637894', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637779', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642034', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640079', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639044', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638469', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638239', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638009', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.804 | Q34 | What are the names of the genes that are targeted by the drug Estradiol in the treatment of Premature ovarian insufficiency? | In the context of Premature ovarian insufficiency, the drug Estradiol targets the gene estrogen receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%premature ovarian insufficiency%" OR LOWER(efo_term) LIKE "%premature ovarian insufficiency%") AND (LOWER(drugName) LIKE "%estradiol%" OR LOWER(tradeNames_list) LIKE "%estradiol%" OR LOWER(syns_list) LIKE "%estradiol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_824178', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824328', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824378', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824428', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824528', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824578', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824628', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824728', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824778', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824828', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824878', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825078', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825128', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825178', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825228', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825278', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825328', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825378', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825428', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825528', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825578', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825628', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825678', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825728', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825828', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825878', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826078', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826128', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826178', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826228', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826278', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826328', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826378', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826428', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826478', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826528', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826578', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826628', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826678', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826728', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826778', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826828', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826878', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827128', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827178', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827228', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827278', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827328', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827378', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827478', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827528', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827578', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827628', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827678', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827728', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827778', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827828', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827878', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_828028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827078', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825478', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824678', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824278', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824078', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827428', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825778', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824478', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824228', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824128', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.633 | Q34 | What are the names of the genes that are targeted by the drug Sorafenib in the treatment of neoplasm? | In the context of neoplasm, the drug Sorafenib targets the gene kinase insert domain receptor, B-Raf proto-oncogene, serine/threonine kinase, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and ret proto-oncogene. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%sorafenib%" OR LOWER(tradeNames_list) LIKE "%sorafenib%" OR LOWER(syns_list) LIKE "%sorafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_684091', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684274', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683968', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683844', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684088', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683295', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684152', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683480', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684334', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683661', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684576', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684637', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683907', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684942', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684883', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684944', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_683234', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685066', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_683298', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685125', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684151', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683542', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683541', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683539', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684335', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683600', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683663', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684579', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684515', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683786', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683358', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684640', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683846', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684698', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683908', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_685006', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684027', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684884', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684030', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_685005', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684090', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_685003', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684945', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685186', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_683297', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685064', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_683237', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685128', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685067', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685127', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684149', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683419', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683969', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683722', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684271', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683481', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684213', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684456', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684332', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683603', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683602', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684454', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684393', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684396', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683664', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684762', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_683725', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684518', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684517', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684578', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683356', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683785', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683359', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684761', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_683966', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684639', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683847', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684759', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_683905', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684701', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684700', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685188', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_683417', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684823', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684822', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685247', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685189', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684820', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684457', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684273', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684210', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683478', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683420', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684212', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684395', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683783', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684881', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_683236', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683724', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684029', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1303 | Q34 | What are the names of the genes that are targeted by the drug Nitroglycerin in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Nitroglycerin targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%nitroglycerin%" OR LOWER(tradeNames_list) LIKE "%nitroglycerin%" OR LOWER(syns_list) LIKE "%nitroglycerin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972644', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972712', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972576', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972508', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972474', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972678', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972610', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972542', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.307 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227762', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228617', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228902', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229187', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229757', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230042', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230327', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230897', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231182', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231467', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231752', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232322', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230612', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227192', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226622', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232037', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229472', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228047', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227477', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226907', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1751 | Q34 | What are the names of the genes that are targeted by the drug Omeprazole in the treatment of Peptic ulcer? | In the context of Peptic ulcer, the drug Omeprazole targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%peptic ulcer%" OR LOWER(efo_term) LIKE "%peptic ulcer%") AND (LOWER(drugName) LIKE "%omeprazole%" OR LOWER(tradeNames_list) LIKE "%omeprazole%" OR LOWER(syns_list) LIKE "%omeprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1098180', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098104', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098040', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098174', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098244', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098314', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098320', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097970', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098110', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098250', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098034', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097964', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097867', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097891', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097855', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097879', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1802 | Q34 | What are the names of the genes that are targeted by the drug Famotidine in the treatment of gastroesophageal reflux disease? | In the context of gastroesophageal reflux disease, the drug Famotidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastroesophageal reflux disease%" OR LOWER(efo_term) LIKE "%gastroesophageal reflux disease%") AND (LOWER(drugName) LIKE "%famotidine%" OR LOWER(tradeNames_list) LIKE "%famotidine%" OR LOWER(syns_list) LIKE "%famotidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100336', 'drugName': 'Famotidine', 'tradeNames_list': "['Famotidine', 'Famotidine preservative freeFamotidine preservative free (pharmacy bulk)', 'Fluxid', 'PepcidPepcid ac', 'Pepcid preservative free', 'Pepcid rpd']", 'syns_list': "['Amfamox', 'Fadul', 'Famodil', 'Famosan', 'Famotidine', 'Famoxal', 'GanorGastridin', 'Gastropen', 'L 643341', 'Lecedil', 'MK-208', 'Motiax', 'MucloxNSC-757810', 'Pepcidac', 'Pepdine', 'Pepdul', 'YM-11170']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1677 | Q34 | What are the names of the genes that are targeted by the drug Aliskiren Fumarate in the treatment of stroke? | In the context of stroke, the drug Aliskiren Fumarate targets the gene renin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%aliskiren fumarate%" OR LOWER(tradeNames_list) LIKE "%aliskiren fumarate%" OR LOWER(syns_list) LIKE "%aliskiren fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095565', 'drugName': 'Aliskiren Fumarate', 'tradeNames_list': "['Tekturna']", 'syns_list': "['Aliskiren fumarate', 'Aliskiren hemifumarate', 'NSC-759185', 'SPP-100BSPP100']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'REN', 'approvedName': 'renin'}, {'UUID': 'DrugTargetsIndication121923_text_1095563', 'drugName': 'Aliskiren Fumarate', 'tradeNames_list': "['Tekturna']", 'syns_list': "['Aliskiren fumarate', 'Aliskiren hemifumarate', 'NSC-759185', 'SPP-100BSPP100']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'REN', 'approvedName': 'renin'}, {'UUID': 'DrugTargetsIndication121923_text_1095569', 'drugName': 'Aliskiren Fumarate', 'tradeNames_list': "['Tekturna']", 'syns_list': "['Aliskiren fumarate', 'Aliskiren hemifumarate', 'NSC-759185', 'SPP-100BSPP100']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'REN', 'approvedName': 'renin'}, {'UUID': 'DrugTargetsIndication121923_text_1095567', 'drugName': 'Aliskiren Fumarate', 'tradeNames_list': "['Tekturna']", 'syns_list': "['Aliskiren fumarate', 'Aliskiren hemifumarate', 'NSC-759185', 'SPP-100BSPP100']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'REN', 'approvedName': 'renin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.102 | Q34 | What are the names of the genes that are targeted by the drug Granisetron in the treatment of Chemotherapy-induced nausea and vomiting? | In the context of Chemotherapy-induced nausea and vomiting, the drug Granisetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chemotherapy-induced nausea and vomiting%" OR LOWER(efo_term) LIKE "%chemotherapy-induced nausea and vomiting%") AND (LOWER(drugName) LIKE "%granisetron%" OR LOWER(tradeNames_list) LIKE "%granisetron%" OR LOWER(syns_list) LIKE "%granisetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205782', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205809', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205810', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205823', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205796', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205768', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205754', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205753', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205824', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205795', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205781', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205767', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.938 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of common cold? | In the context of common cold, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%common cold%" OR LOWER(efo_term) LIKE "%common cold%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840169', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840406', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840485', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840564', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840722', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840801', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840880', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841038', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841117', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841196', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841275', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841433', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841512', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841591', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841670', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841749', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840959', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840327', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840011', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839853', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839774', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841354', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840643', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840248', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840090', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839932', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1919 | Q34 | What are the names of the genes that are targeted by the drug Mipomersen Sodium in the treatment of familial hypercholesterolemia? | In the context of familial hypercholesterolemia, the drug Mipomersen Sodium targets the gene apolipoprotein B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial hypercholesterolemia%" OR LOWER(efo_term) LIKE "%familial hypercholesterolemia%") AND (LOWER(drugName) LIKE "%mipomersen sodium%" OR LOWER(tradeNames_list) LIKE "%mipomersen sodium%" OR LOWER(syns_list) LIKE "%mipomersen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191789', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'syns_list': "['ISIS 301012', 'ISIS-301012', 'Mipomersen sodium', 'Mipomersen sodium salt']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B'}, {'UUID': 'DrugTargetsIndication121923_text_1191792', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'syns_list': "['ISIS 301012', 'ISIS-301012', 'Mipomersen sodium', 'Mipomersen sodium salt']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B'}, {'UUID': 'DrugTargetsIndication121923_text_1191795', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'syns_list': "['ISIS 301012', 'ISIS-301012', 'Mipomersen sodium', 'Mipomersen sodium salt']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.305 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of acne? | In the context of acne, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acne%" OR LOWER(efo_term) LIKE "%acne%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227760', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228615', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228900', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229185', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229755', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230040', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230325', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230895', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231180', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231465', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231750', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232320', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230610', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228330', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227190', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226620', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226335', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232035', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229470', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228045', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227475', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226905', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1115 | Q34 | What are the names of the genes that are targeted by the drug Ivosidenib in the treatment of cancer? | In the context of cancer, the drug Ivosidenib targets the gene isocitrate dehydrogenase (NADP(+)) 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%ivosidenib%" OR LOWER(tradeNames_list) LIKE "%ivosidenib%" OR LOWER(syns_list) LIKE "%ivosidenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924605', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924632', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924641', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924650', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924668', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924677', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924686', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924704', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924713', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924722', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924731', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924749', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924758', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924767', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924776', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924785', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924794', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924695', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924623', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924587', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924569', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924560', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924740', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924659', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924614', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924596', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924578', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1040 | Q34 | What are the names of the genes that are targeted by the drug Ziconotide Acetate in the treatment of pain? | In the context of pain, the drug Ziconotide Acetate targets the gene calcium voltage-gated channel subunit alpha1 B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%ziconotide acetate%" OR LOWER(tradeNames_list) LIKE "%ziconotide acetate%" OR LOWER(syns_list) LIKE "%ziconotide acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_891741', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891747', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891749', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891751', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891755', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891757', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891759', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891763', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891765', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891767', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891769', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891745', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891737', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891733', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891731', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891761', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891753', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891743', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891739', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891735', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.895 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of pain? | In the context of pain, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838064', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838081', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838093', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838097', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838110', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838114', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838115', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838131', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838132', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838144', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838148', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838161', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838165', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838166', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838178', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838182', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838183', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838195', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838199', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838200', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838212', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838217', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838229', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838233', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838234', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838246', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838251', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838263', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838267', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838268', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838280', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838284', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838285', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838297', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838301', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838302', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838216', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838127', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838080', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838059', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838046', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838042', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838250', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838149', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838098', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838076', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838063', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838047', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1415 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of spotted fever? | In the context of spotted fever, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spotted fever%" OR LOWER(efo_term) LIKE "%spotted fever%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038004', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038139', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038154', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038214', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038289', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038304', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038364', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038439', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038454', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038514', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038529', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038604', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038664', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038679', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038739', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038754', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038814', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038829', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038889', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038904', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038964', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039039', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039054', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039114', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039129', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039189', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039264', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039279', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039339', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039354', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039414', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039429', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039489', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039504', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039564', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039579', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039639', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039654', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039714', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039729', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039789', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039804', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039864', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039879', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039939', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039954', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040014', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040029', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040089', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040104', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040164', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040239', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040254', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040314', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040329', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040389', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040404', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040479', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040539', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040554', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040614', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040629', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040689', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040704', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040764', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040779', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040839', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040854', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040914', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040929', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040989', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041004', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041064', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041079', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040179', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038979', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038379', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038079', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037929', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037854', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037839', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040464', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039204', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038589', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038229', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spotted Fever Group Rickettsiosis', 'efo_term': 'spotted fever', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038064', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037989', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037914', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rocky Mountain Spotted Fever', 'efo_term': None, 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.590 | Q34 | What are the names of the genes that are targeted by the drug Carbamazepine in the treatment of trigeminal neuralgia? | In the context of trigeminal neuralgia, the drug Carbamazepine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%trigeminal neuralgia%" OR LOWER(efo_term) LIKE "%trigeminal neuralgia%") AND (LOWER(drugName) LIKE "%carbamazepine%" OR LOWER(tradeNames_list) LIKE "%carbamazepine%" OR LOWER(syns_list) LIKE "%carbamazepine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_650987', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651035', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651051', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651067', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651099', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651115', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651131', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651163', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651179', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651195', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651211', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651243', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651259', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651275', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651291', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651307', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651323', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651339', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651355', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651371', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651387', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651419', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651435', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651451', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651467', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651483', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651515', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651531', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651547', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651563', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651579', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651595', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651611', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651627', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651643', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651659', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651675', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651691', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651707', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651723', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651739', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651755', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651771', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651787', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651803', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651819', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651835', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651851', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651867', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651883', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651899', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651931', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651947', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651963', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_651979', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_651995', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652011', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652043', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652059', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652075', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652091', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652107', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652123', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652139', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652155', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652171', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652187', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652203', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652219', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652235', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652251', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652267', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652283', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652299', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652315', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652331', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652347', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652363', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652379', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652395', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652411', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652427', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652443', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652459', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652475', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652491', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_651915', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651403', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651147', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651019', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650955', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650923', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650907', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652027', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_651499', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651227', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651083', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651003', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650971', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650939', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trigeminal Neuralgia', 'efo_term': 'trigeminal neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.241 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of pain? | In the context of pain, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222006', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221941', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222331', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222201', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221876', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222266', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222071', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222136', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222095', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222160', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222290', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221965', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221900', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221835', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222225', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222030', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1444 | Q34 | What are the names of the genes that are targeted by the drug Clevidipine in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Clevidipine targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%clevidipine%" OR LOWER(tradeNames_list) LIKE "%clevidipine%" OR LOWER(syns_list) LIKE "%clevidipine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1044221', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044239', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044245', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044251', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044263', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044269', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044275', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044287', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044293', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044299', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044305', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044317', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044323', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044329', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044335', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044341', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044347', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044353', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044359', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044365', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044371', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044383', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044389', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044395', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044401', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044377', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044233', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044209', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044197', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044191', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044281', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044311', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044257', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044227', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044215', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044203', 'drugName': 'Clevidipine', 'tradeNames_list': "['Cleviprex']", 'syns_list': "['Clevidepine', 'Clevidepine butyrate', 'Clevidipine', 'Clevidipine butyrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1903 | Q34 | What are the names of the genes that are targeted by the drug Bimatoprost in the treatment of glaucoma? | In the context of glaucoma, the drug Bimatoprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%glaucoma%" OR LOWER(efo_term) LIKE "%glaucoma%") AND (LOWER(drugName) LIKE "%bimatoprost%" OR LOWER(tradeNames_list) LIKE "%bimatoprost%" OR LOWER(syns_list) LIKE "%bimatoprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149148', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149165', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149166', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149174', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149183', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149184', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149192', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149201', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149202', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149210', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149211', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149220', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149228', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149229', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149237', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149238', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149246', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149247', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149255', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149256', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149264', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149273', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149274', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149282', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149283', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149291', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149300', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149301', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149309', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149310', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149318', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149319', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149327', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149328', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149336', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149337', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149345', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149346', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149354', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149355', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149363', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149364', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149372', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149373', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149381', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149382', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149390', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149391', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149399', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149400', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149265', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149193', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149157', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149139', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149130', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149129', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149292', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149219', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149175', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149156', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149147', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149138', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.992 | Q34 | What are the names of the genes that are targeted by the drug Oxybutynin Chloride in the treatment of overactive bladder? | In the context of overactive bladder, the drug Oxybutynin Chloride targets the gene cholinergic receptor muscarinic 3 and cholinergic receptor muscarinic 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%overactive bladder%" OR LOWER(efo_term) LIKE "%overactive bladder%") AND (LOWER(drugName) LIKE "%oxybutynin chloride%" OR LOWER(tradeNames_list) LIKE "%oxybutynin chloride%" OR LOWER(syns_list) LIKE "%oxybutynin chloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857277', 'drugName': 'Oxybutynin Chloride', 'tradeNames_list': "['Ditropan', 'Ditropan xl', 'Gelnique', 'Oxybutynin chloride']", 'syns_list': "['5058', 'MJ 4309-1', 'MJ-4309-1', 'NSC-759108', 'Oxybutynin chlorideOxybutynin hydrochloride', 'Pollakisu', 'Tropax']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857265', 'drugName': 'Oxybutynin Chloride', 'tradeNames_list': "['Ditropan', 'Ditropan xl', 'Gelnique', 'Oxybutynin chloride']", 'syns_list': "['5058', 'MJ 4309-1', 'MJ-4309-1', 'NSC-759108', 'Oxybutynin chlorideOxybutynin hydrochloride', 'Pollakisu', 'Tropax']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857262', 'drugName': 'Oxybutynin Chloride', 'tradeNames_list': "['Ditropan', 'Ditropan xl', 'Gelnique', 'Oxybutynin chloride']", 'syns_list': "['5058', 'MJ 4309-1', 'MJ-4309-1', 'NSC-759108', 'Oxybutynin chlorideOxybutynin hydrochloride', 'Pollakisu', 'Tropax']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857271', 'drugName': 'Oxybutynin Chloride', 'tradeNames_list': "['Ditropan', 'Ditropan xl', 'Gelnique', 'Oxybutynin chloride']", 'syns_list': "['5058', 'MJ 4309-1', 'MJ-4309-1', 'NSC-759108', 'Oxybutynin chlorideOxybutynin hydrochloride', 'Pollakisu', 'Tropax']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857274', 'drugName': 'Oxybutynin Chloride', 'tradeNames_list': "['Ditropan', 'Ditropan xl', 'Gelnique', 'Oxybutynin chloride']", 'syns_list': "['5058', 'MJ 4309-1', 'MJ-4309-1', 'NSC-759108', 'Oxybutynin chlorideOxybutynin hydrochloride', 'Pollakisu', 'Tropax']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857268', 'drugName': 'Oxybutynin Chloride', 'tradeNames_list': "['Ditropan', 'Ditropan xl', 'Gelnique', 'Oxybutynin chloride']", 'syns_list': "['5058', 'MJ 4309-1', 'MJ-4309-1', 'NSC-759108', 'Oxybutynin chlorideOxybutynin hydrochloride', 'Pollakisu', 'Tropax']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.558 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine Hydrochloride in the treatment of Back pain? | In the context of Back pain, the drug Lidocaine Hydrochloride targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%back pain%" OR LOWER(efo_term) LIKE "%back pain%") AND (LOWER(drugName) LIKE "%lidocaine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%lidocaine hydrochloride%" OR LOWER(syns_list) LIKE "%lidocaine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637007', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637067', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637087', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637107', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637147', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637167', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637187', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637227', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637247', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637267', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637287', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637327', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637347', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637367', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637387', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637407', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637427', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637447', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637467', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637487', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637507', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637547', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637567', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637587', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637607', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637627', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637667', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637687', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637527', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637207', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637047', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636967', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636927', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636907', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637647', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637307', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637127', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637027', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636987', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636947', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.580 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of Tendinopathy? | In the context of Tendinopathy, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%tendinopathy%" OR LOWER(efo_term) LIKE "%tendinopathy%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638370', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638715', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638830', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638945', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639175', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639290', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639405', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639635', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639750', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639865', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639980', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640210', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640325', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640440', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640555', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640670', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640785', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640900', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641015', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641130', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641245', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641475', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641590', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641705', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641820', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641935', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642165', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642280', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642395', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642510', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642625', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642740', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642855', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642970', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643085', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643200', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643315', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643430', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643545', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643660', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643775', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643890', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644005', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644120', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644235', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644350', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644465', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644580', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641360', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639520', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638600', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638140', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637910', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637795', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642050', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640095', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639060', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638485', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638255', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638025', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1054 | Q34 | What are the names of the genes that are targeted by the drug Fluorouracil in the treatment of adenocarcinoma? | In the context of adenocarcinoma, the drug Fluorouracil targets the gene thymidylate synthetase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%adenocarcinoma%" OR LOWER(efo_term) LIKE "%adenocarcinoma%") AND (LOWER(drugName) LIKE "%fluorouracil%" OR LOWER(tradeNames_list) LIKE "%fluorouracil%" OR LOWER(syns_list) LIKE "%fluorouracil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919462', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919440', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'colon adenocarcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919400', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Adenocarcinoma, Mucinous', 'efo_term': 'mucinous carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919404', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919409', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919405', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.117 | Q34 | What are the names of the genes that are targeted by the drug Escitalopram Oxalate in the treatment of anxiety disorder? | In the context of anxiety disorder, the drug Escitalopram Oxalate targets the gene solute carrier family 6 member 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anxiety disorder%" OR LOWER(efo_term) LIKE "%anxiety disorder%") AND (LOWER(drugName) LIKE "%escitalopram oxalate%" OR LOWER(tradeNames_list) LIKE "%escitalopram oxalate%" OR LOWER(syns_list) LIKE "%escitalopram oxalate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206513', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206522', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206529', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206530', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206538', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206539', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206540', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206548', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206549', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206556', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206557', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206565', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206566', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206567', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206574', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206575', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206576', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206583', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206584', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206585', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206592', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206594', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206601', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206602', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206603', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206593', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206521', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206511', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206503', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206502', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206547', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206558', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206531', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206520', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206512', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206504', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.601 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of bipolar I disorder? | In the context of bipolar I disorder, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar i disorder%" OR LOWER(efo_term) LIKE "%bipolar i disorder%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653155', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653248', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653279', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653310', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653372', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653403', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653434', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653496', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653527', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653558', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653589', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653651', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653682', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653713', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653744', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653775', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653806', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653837', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653868', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653899', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653930', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653992', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654023', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654054', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654085', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654116', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654178', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654209', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654240', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654271', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654302', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654333', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654364', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654395', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654426', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654457', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654488', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654519', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654550', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654581', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654612', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654643', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654674', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654705', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654736', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654767', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654798', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654829', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654860', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654891', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654922', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654984', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655015', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655046', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655077', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655108', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655139', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655201', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655232', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655263', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655294', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655325', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655356', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655387', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655418', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655449', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655480', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655511', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655542', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655573', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655604', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655635', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655666', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655697', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655728', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655759', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655790', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655821', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655852', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655883', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655914', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655945', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655976', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656007', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656038', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656069', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_654953', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_653961', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653465', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653217', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653093', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653031', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653000', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_655170', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654147', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_653620', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653341', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653186', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653124', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653062', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.812 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of Myalgia? | In the context of Myalgia, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myalgia%" OR LOWER(efo_term) LIKE "%myalgia%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828369', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828471', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828505', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828539', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828437', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828301', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828233', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828199', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828573', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828403', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828335', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828267', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.659 | Q34 | What are the names of the genes that are targeted by the drug Tolvaptan in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Tolvaptan targets the gene arginine vasopressin receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%tolvaptan%" OR LOWER(tradeNames_list) LIKE "%tolvaptan%" OR LOWER(syns_list) LIKE "%tolvaptan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695169', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695214', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695229', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695244', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695274', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695289', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695304', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695319', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695199', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695139', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695109', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695094', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695259', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695184', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695154', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695124', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1634 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of stroke? | Dabigatran has not been approved by the FDA as a treatment for stroke, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092534', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092504', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092379', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092384', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092429', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092574', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092369', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092464', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092544', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092394', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092424', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092484', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092579', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092609', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092449', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092489', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092644', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092624', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092479', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092514', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092519', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092374', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092524', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092419', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092589', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092549', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092414', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092564', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092569', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092619', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092584', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092499', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092469', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092399', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092454', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092604', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092529', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092639', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092494', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092434', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092594', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092554', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092634', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092559', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092649', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092509', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092389', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092599', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092614', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092459', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092404', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092539', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092409', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092629', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092439', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092474', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092444', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093193', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093206', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092686', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092699', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092660', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092738', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092751', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092764', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092777', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092712', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092803', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092816', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092829', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092842', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092855', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092868', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093089', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092894', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092907', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092920', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092933', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093037', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092946', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092881', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092959', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092972', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092985', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092998', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093141', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093011', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093024', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093050', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093063', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092790', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093076', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093102', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093115', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093128', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092673', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093154', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093167', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093180', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092725', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1682 | Q34 | What are the names of the genes that are targeted by the drug Ertugliflozin in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Ertugliflozin targets the gene solute carrier family 5 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%ertugliflozin%" OR LOWER(tradeNames_list) LIKE "%ertugliflozin%" OR LOWER(syns_list) LIKE "%ertugliflozin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096239', 'drugName': 'Ertugliflozin', 'tradeNames_list': "['Steglatro']", 'syns_list': "['Ertugliflozin', 'Ertugliflozin l-pyroglutamic acidErtugliflozin pidolate', 'MK-8835', 'PF-04971729', 'PF-04971729-00PF04971729', 'Pf-04971729']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096238', 'drugName': 'Ertugliflozin', 'tradeNames_list': "['Steglatro']", 'syns_list': "['Ertugliflozin', 'Ertugliflozin l-pyroglutamic acidErtugliflozin pidolate', 'MK-8835', 'PF-04971729', 'PF-04971729-00PF04971729', 'Pf-04971729']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096242', 'drugName': 'Ertugliflozin', 'tradeNames_list': "['Steglatro']", 'syns_list': "['Ertugliflozin', 'Ertugliflozin l-pyroglutamic acidErtugliflozin pidolate', 'MK-8835', 'PF-04971729', 'PF-04971729-00PF04971729', 'Pf-04971729']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096241', 'drugName': 'Ertugliflozin', 'tradeNames_list': "['Steglatro']", 'syns_list': "['Ertugliflozin', 'Ertugliflozin l-pyroglutamic acidErtugliflozin pidolate', 'MK-8835', 'PF-04971729', 'PF-04971729-00PF04971729', 'Pf-04971729']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1297 | Q34 | What are the names of the genes that are targeted by the drug Dasiglucagon Hydrochloride in the treatment of type 1 diabetes mellitus? | In the context of type 1 diabetes mellitus, the drug Dasiglucagon Hydrochloride targets the gene glucagon receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 1 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 1 diabetes mellitus%") AND (LOWER(drugName) LIKE "%dasiglucagon hydrochloride%" OR LOWER(tradeNames_list) LIKE "%dasiglucagon hydrochloride%" OR LOWER(syns_list) LIKE "%dasiglucagon hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_968351', 'drugName': 'Dasiglucagon Hydrochloride', 'tradeNames_list': "['Zegalogue', 'Zegalogue (autoinjector)']", 'syns_list': "['Dasiglucagon hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968353', 'drugName': 'Dasiglucagon Hydrochloride', 'tradeNames_list': "['Zegalogue', 'Zegalogue (autoinjector)']", 'syns_list': "['Dasiglucagon hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.484 | Q34 | What are the names of the genes that are targeted by the drug Lisdexamfetamine Dimesylate in the treatment of glaucoma? | In the context of glaucoma, the drug Lisdexamfetamine Dimesylate targets the gene solute carrier family 6 member 2, solute carrier family 18 member A2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%glaucoma%" OR LOWER(efo_term) LIKE "%glaucoma%") AND (LOWER(drugName) LIKE "%lisdexamfetamine dimesylate%" OR LOWER(tradeNames_list) LIKE "%lisdexamfetamine dimesylate%" OR LOWER(syns_list) LIKE "%lisdexamfetamine dimesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_419191', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419224', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419235', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419246', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419268', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419279', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419290', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419312', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419323', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419334', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419345', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419367', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419378', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419389', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419400', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419411', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419422', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419433', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419444', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419455', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419466', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419488', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419499', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419510', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419521', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419532', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419554', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419565', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419576', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419587', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419598', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419609', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419620', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419631', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419642', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419653', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419664', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419675', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419686', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419697', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419708', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419719', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419730', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419741', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419752', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419763', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419774', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419785', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419796', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419807', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419818', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419840', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419851', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419862', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419873', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419884', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419895', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419917', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419928', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419939', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419950', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419961', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419972', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419983', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419994', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420005', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420016', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420027', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420038', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420049', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420060', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420071', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420082', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420093', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420104', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420115', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420126', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420137', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420148', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420159', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420170', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420181', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420192', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420203', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420214', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420225', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419829', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419477', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419301', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419213', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419169', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419147', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419136', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419906', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419543', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419356', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419257', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419202', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419180', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419158', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.363 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232452', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232505', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232506', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232532', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232559', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232560', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232586', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232613', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232614', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232640', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232641', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232668', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232694', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232695', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232721', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232722', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232748', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232749', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232775', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232776', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232802', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232829', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232830', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232856', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232857', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232883', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232910', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232911', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232937', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232938', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232964', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232965', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232991', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232992', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233018', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233019', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233045', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233046', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233072', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233073', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233099', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233100', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233126', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233127', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233153', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233154', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233180', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233181', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233207', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233208', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233234', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233261', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233262', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233288', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233289', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233315', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233316', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233343', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233369', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233370', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233396', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233397', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233423', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233424', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233450', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233451', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233477', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233478', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233504', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233505', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233531', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233532', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233558', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233559', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233585', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233586', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233612', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233613', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233639', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233640', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233666', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233667', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233693', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233694', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233720', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233721', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233235', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232803', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232587', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232479', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232425', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232398', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232397', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233342', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232884', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232667', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232533', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232478', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232451', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232424', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.616 | Q34 | What are the names of the genes that are targeted by the drug Cabozantinib S-Malate in the treatment of thyroid cancer? | In the context of thyroid cancer, the drug Cabozantinib S-Malate targets the gene kinase insert domain receptor and MET proto-oncogene, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid cancer%" OR LOWER(efo_term) LIKE "%thyroid cancer%") AND (LOWER(drugName) LIKE "%cabozantinib s-malate%" OR LOWER(tradeNames_list) LIKE "%cabozantinib s-malate%" OR LOWER(syns_list) LIKE "%cabozantinib s-malate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_669676', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669745', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669768', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669791', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669837', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669860', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669883', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669929', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669952', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669975', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669998', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670044', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670067', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670090', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670113', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670136', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670159', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670182', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670205', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670228', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670251', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670297', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670320', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670343', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670366', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670389', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670435', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670458', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670481', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670504', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670527', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670550', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670573', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670596', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670619', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670642', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670665', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670688', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670711', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670734', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670757', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670780', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670803', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670826', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670849', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670872', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670895', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670918', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670941', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670964', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670987', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671033', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671056', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671079', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671102', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671125', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671148', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671194', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671217', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671240', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671263', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671286', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671309', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671332', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671355', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671378', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671401', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671424', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671447', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671470', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671493', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671516', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671539', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671562', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671585', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671608', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671631', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671654', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671677', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671700', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671723', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671746', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671769', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671792', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671815', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671838', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671010', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_670274', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669906', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669722', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669630', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669584', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669561', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_671171', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_670412', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670021', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669814', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669699', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669653', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669607', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.770 | Q34 | What are the names of the genes that are targeted by the drug Sufentanil Citrate in the treatment of pain? | In the context of pain, the drug Sufentanil Citrate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%sufentanil citrate%" OR LOWER(tradeNames_list) LIKE "%sufentanil citrate%" OR LOWER(syns_list) LIKE "%sufentanil citrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_789341', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789344', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789345', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789346', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789348', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789349', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789350', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789352', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789353', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789351', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789343', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789337', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789336', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789339', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789347', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789342', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789340', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789338', 'drugName': 'Sufentanil Citrate', 'tradeNames_list': "['Dsuvia', 'Sufenta', 'Sufenta preservative free', 'SufentalSufentanil citrate']", 'syns_list': "['R 33800', 'R-33800', 'Sufentanil citrate', 'Sufentanil citrate cii']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1585 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of angiomyolipoma? | In the context of angiomyolipoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%angiomyolipoma%" OR LOWER(efo_term) LIKE "%angiomyolipoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085238', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085504', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085508', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085639', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085774', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085778', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085909', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086044', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086048', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086179', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086183', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086318', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086449', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086453', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086584', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086588', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086719', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086723', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086854', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086858', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086989', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087124', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087128', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087259', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087263', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087394', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087529', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087533', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087664', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087668', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087799', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087803', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087934', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087938', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088069', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088073', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088204', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088208', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088339', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088343', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088474', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088478', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088609', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088613', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088744', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088748', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088879', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088883', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089014', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089018', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089149', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089284', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089288', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089419', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089423', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089554', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089558', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089693', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089824', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089828', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089959', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089963', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090094', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090098', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090229', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090233', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090364', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090368', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090499', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090503', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090634', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090638', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089153', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086993', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085913', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085373', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085103', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084968', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084964', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089689', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087398', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086314', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085643', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085369', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085234', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085099', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.175 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of ankylosing spondylitis? | In the context of ankylosing spondylitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ankylosing spondylitis%" OR LOWER(efo_term) LIKE "%ankylosing spondylitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218681', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219305', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219513', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219721', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220137', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220345', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220553', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220761', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219097', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218265', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217849', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217641', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219929', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218889', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218473', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218057', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1828 | Q34 | What are the names of the genes that are targeted by the drug Cyclosporine in the treatment of psoriasis? | In the context of psoriasis, the drug Cyclosporine targets the gene peptidylprolyl isomerase A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis%" OR LOWER(efo_term) LIKE "%psoriasis%") AND (LOWER(drugName) LIKE "%cyclosporine%" OR LOWER(tradeNames_list) LIKE "%cyclosporine%" OR LOWER(syns_list) LIKE "%cyclosporine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1101281', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101662', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101789', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101916', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102170', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102297', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102424', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102678', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102805', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102932', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1103059', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101535', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101027', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100773', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100646', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102551', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102043', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101408', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101154', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100900', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1318 | Q34 | What are the names of the genes that are targeted by the drug Nitric Oxide in the treatment of Respiratory insufficiency? | In the context of Respiratory insufficiency, the drug Nitric Oxide targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%respiratory insufficiency%" OR LOWER(efo_term) LIKE "%respiratory insufficiency%") AND (LOWER(drugName) LIKE "%nitric oxide%" OR LOWER(tradeNames_list) LIKE "%nitric oxide%" OR LOWER(syns_list) LIKE "%nitric oxide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_974262', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974367', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974370', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974421', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974475', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974478', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974529', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974583', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974586', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974637', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974640', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974694', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974745', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974748', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974799', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974802', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974853', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974856', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974907', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974910', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974961', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975015', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975018', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975069', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975072', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975123', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975177', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975180', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975231', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975234', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975285', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975288', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975339', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975342', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975393', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975396', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975447', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975450', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975501', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975504', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975555', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975558', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975609', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975612', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975663', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975666', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975717', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975720', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975771', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975774', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975825', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975879', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975882', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975933', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975936', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975987', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975990', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976044', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976095', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976098', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976149', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976152', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976203', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976206', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976257', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976260', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976311', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976314', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976365', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976368', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976419', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976422', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976473', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976476', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976527', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976530', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976581', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976584', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976635', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976638', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976689', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976692', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976743', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976746', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976797', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976800', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975828', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974964', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974532', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974316', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974208', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974154', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974151', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976041', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975126', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974691', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974424', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974313', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974259', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974205', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1250 | Q34 | What are the names of the genes that are targeted by the drug Armodafinil in the treatment of obstructive sleep apnea? | In the context of obstructive sleep apnea, the drug Armodafinil targets the gene solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%obstructive sleep apnea%" OR LOWER(efo_term) LIKE "%obstructive sleep apnea%") AND (LOWER(drugName) LIKE "%armodafinil%" OR LOWER(tradeNames_list) LIKE "%armodafinil%" OR LOWER(syns_list) LIKE "%armodafinil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939100', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939157', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939176', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939195', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939233', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939252', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939271', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939309', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939328', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939347', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939366', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939138', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939062', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939024', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939005', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939290', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939214', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939119', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939081', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939043', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1241 | Q34 | What are the names of the genes that are targeted by the drug Vibegron in the treatment of overactive bladder? | In the context of overactive bladder, the drug Vibegron targets the gene adrenoceptor beta 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%overactive bladder%" OR LOWER(efo_term) LIKE "%overactive bladder%") AND (LOWER(drugName) LIKE "%vibegron%" OR LOWER(tradeNames_list) LIKE "%vibegron%" OR LOWER(syns_list) LIKE "%vibegron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938261', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'syns_list': "['KRP-114V', 'Mk4618', 'Vibegron']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938266', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'syns_list': "['KRP-114V', 'Mk4618', 'Vibegron']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.735 | Q34 | What are the names of the genes that are targeted by the drug Naloxegol Oxalate in the treatment of constipation disorder? | In the context of constipation disorder, the drug Naloxegol Oxalate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%constipation disorder%" OR LOWER(efo_term) LIKE "%constipation disorder%") AND (LOWER(drugName) LIKE "%naloxegol oxalate%" OR LOWER(tradeNames_list) LIKE "%naloxegol oxalate%" OR LOWER(syns_list) LIKE "%naloxegol oxalate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763361', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763367', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763369', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763371', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763365', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763357', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763353', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763351', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763373', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763363', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763359', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763355', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'syns_list': "['AZ13337019 oxalate', 'NKTR-118 oxalate', 'Naloxegol oxalate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.697 | Q34 | What are the names of the genes that are targeted by the drug Apixaban in the treatment of stroke? | In the context of stroke, the drug Apixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%apixaban%" OR LOWER(tradeNames_list) LIKE "%apixaban%" OR LOWER(syns_list) LIKE "%apixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710478', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710536', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710594', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710681', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710710', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710768', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710391', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710507', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710420', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710565', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710362', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710739', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710652', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710449', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710623', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710338', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710396', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710454', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710599', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710483', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710628', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710570', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710657', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710367', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710512', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710686', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710715', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710425', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710744', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710541', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.80 | Q34 | What are the names of the genes that are targeted by the drug Bromocriptine Mesylate in the treatment of acromegaly? | In the context of acromegaly, the drug Bromocriptine Mesylate targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acromegaly%" OR LOWER(efo_term) LIKE "%acromegaly%") AND (LOWER(drugName) LIKE "%bromocriptine mesylate%" OR LOWER(tradeNames_list) LIKE "%bromocriptine mesylate%" OR LOWER(syns_list) LIKE "%bromocriptine mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201376', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201397', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201404', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201411', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201425', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201432', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201439', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201453', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201460', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201467', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201474', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201488', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201495', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201502', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201509', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201516', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201523', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201530', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201537', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201544', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201551', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201565', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201572', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201579', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201586', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201593', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201607', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201614', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201621', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201628', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201635', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201642', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201649', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201656', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201663', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201670', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201677', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201684', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201691', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201698', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201705', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201712', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201719', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201726', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201733', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201740', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201747', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201754', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201761', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201768', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201775', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201789', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201796', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201803', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201810', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201817', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201824', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201838', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201845', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201852', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201859', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201866', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201873', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201880', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201887', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201894', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201901', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201908', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201915', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201922', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201929', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201936', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201943', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201950', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201957', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201964', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201971', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201978', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201985', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201992', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201999', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202006', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202013', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202020', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202027', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202034', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201782', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201558', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201446', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201390', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201362', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201348', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201341', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201831', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201600', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201481', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201418', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201383', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201369', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201355', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1030 | Q34 | What are the names of the genes that are targeted by the drug Idelalisib in the treatment of cancer? | In the context of cancer, the drug Idelalisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%idelalisib%" OR LOWER(tradeNames_list) LIKE "%idelalisib%" OR LOWER(syns_list) LIKE "%idelalisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858491', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858548', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858567', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858586', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858624', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858643', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858662', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858700', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858719', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858681', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858529', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858415', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858396', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858453', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858605', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858510', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858472', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858434', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.